MedTrace Logo

Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)

NCT02576002 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2691

Last updated 2016-02-26

No results posted yet for this study

Summary

To describe the prevalence, incidence and current treatment and procedures patterns in a US pediatric population with PAH in MarketScan database during the period 2010-2013

Conditions

  • Hypertension, Pulmonary

Interventions

DRUG

Assigned pulmonary hypertension medication

As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02576002 on ClinicalTrials.gov